{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:59:29Z","timestamp":1780372769198,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601437"],"award-info":[{"award-number":["81601437"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771734"],"award-info":[{"award-number":["81771734"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Programme of Guangzhou, China","award":["201804010343"],"award-info":[{"award-number":["201804010343"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.intimp.2019.105700","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T05:03:42Z","timestamp":1560920622000},"page":"105700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3)"],"prefix":"10.1016","volume":"74","author":[{"given":"Chaochen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.105700_bb0005","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1055\/s-0036-1580689","article-title":"Connective tissue disease-associated interstitial lung diseases: unresolved issues","volume":"37","author":"Aparicio","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.intimp.2019.105700_bb0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2019.105700_bb0015","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial lung disease in connective tissue disease\u2014mechanisms and management","volume":"10","author":"Wells","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2019.105700_bb0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis","volume":"3","author":"Akhmetshina","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2019.105700_bb0025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1084\/jem.20110551","article-title":"Integrating mechanisms of pulmonary fibrosis","volume":"208","author":"Wynn","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2019.105700_bb0030","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1159\/000430268","article-title":"Platelet-derived growth factor and transforming growth factor beta1 regulate ARDS-associated lung fibrosis through distinct signaling pathways","volume":"36","author":"Deng","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.intimp.2019.105700_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1183\/09059180.00003214","article-title":"Cellular interactions in the pathogenesis of interstitial lung diseases","volume":"24","author":"Bagnato","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.intimp.2019.105700_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065445","article-title":"Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2","volume":"8","author":"Gabasa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2019.105700_bb0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.0959-9673.2004.00377.x","article-title":"Smad3 as a mediator of the fibrotic response","volume":"85","author":"Flanders","year":"2004","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.intimp.2019.105700_bb0050","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1378\/chest.06-2568","article-title":"Molecular targets in pulmonary fibrosis: the myofibroblast in focus","volume":"132","author":"Scotton","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2019.105700_bb0055","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1074\/jbc.M113.503755","article-title":"The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins","volume":"289","author":"Wei","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2019.105700_bb0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.freeradbiomed.2004.10.033","article-title":"Smad3-ATF3 signaling mediates TGF-beta suppression of genes encoding phase II detoxifying proteins","volume":"38","author":"Bakin","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.intimp.2019.105700_bb0065","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s12272-011-0517-1","article-title":"Suppression of Nrf2 signaling by angiotensin II in murine renal epithelial cells","volume":"34","author":"Kang","year":"2011","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.intimp.2019.105700_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(01)00551-0","article-title":"The molecular biology and nomenclature of the activating transcription factor\/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis","volume":"273","author":"Hai","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.intimp.2019.105700_bb0075","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/annrheumdis-2014-206214","article-title":"Activating transcription factor 3 regulates canonical TGFbeta signalling in systemic sclerosis","volume":"75","author":"Mallano","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2019.105700_bb0080","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2019.105700_bb0085","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2019.105700_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-15-16","article-title":"Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis","volume":"15","author":"Inomata","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2019.105700_bb0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2220\/biomedres.34.309","article-title":"Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways","volume":"34","author":"Ji","year":"2013","journal-title":"Biomed. Res."},{"key":"10.1016\/j.intimp.2019.105700_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.intimp.2019.105700_bb0105","doi-asserted-by":"crossref","first-page":"H512","DOI":"10.1152\/ajpheart.00137.2015","article-title":"Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts","volume":"309","author":"Yamagami","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.intimp.2019.105700_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2019.105700_bb0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fcimb.2017.00440","article-title":"Elimination of mycoplasma contamination from infected human hepatocyte C3A cells by intraperitoneal injection in BALB\/c mice","volume":"7","author":"Weng","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.intimp.2019.105700_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028134","article-title":"In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion","volume":"6","author":"Shi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2019.105700_bb0125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1369\/jhc.7A7287.2007","article-title":"An immunohistochemical method for identifying fibroblasts in formalin-fixed, paraffin-embedded tissue","volume":"56","author":"Goodpaster","year":"2008","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.intimp.2019.105700_bb0130","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2019.105700_bb0135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/art.37853","article-title":"Tumor necrosis factor alpha induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts","volume":"65","author":"Lee","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2019.105700_bb0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2019.105700_bb0145","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00109-009-0520-x","article-title":"ATF3 transcription factor and its emerging roles in immunity and cancer","volume":"87","author":"Thompson","year":"2009","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.intimp.2019.105700_bb0150","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1172\/JCI64410","article-title":"Transcription factor ATF3 links host adaptive response to breast cancer metastasis","volume":"123","author":"Wolford","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2019.105700_bb0155","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1242\/jcs.064915","article-title":"ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells","volume":"123","author":"Yin","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.intimp.2019.105700_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/87e2a80b-3ed7-4ef9-96cb-1268d91b6366","article-title":"Adult cardiac expression of the activating transcription factor 3, ATF3, promotes ventricular hypertrophy","volume":"8","author":"Koren","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2019.105700_bb0165","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0014-4827(02)00015-0","article-title":"TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins","volume":"282","author":"Evans","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.intimp.2019.105700_bb0170","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3748\/wjg.v13.i22.3056","article-title":"Transforming growth factor-beta and fibrosis","volume":"13","author":"Verrecchia","year":"2007","journal-title":"World J. Gastroenterol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919302309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919302309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:19:07Z","timestamp":1761585547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919302309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":34,"alternative-id":["S1567576919302309"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105700","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3)","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105700"}}